Prof Sumanta Kumar Pal and Prof Toni K Choueiri present the findings of their trial, published in The Lancet in June 2023: Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, openlabel, phase 3 trial